Want to join the conversation?
Biopharmaceutical company $AMGN said European Commission (EC) granted marketing authorization for its Kyprolis drug in combination with lenalidomide and dexamethasone for treating adults with multiple myeloma (incurable blood cancer) who have received at least one prior therapy. EC approved Kyprolis based on data from pivotal Phase 3 aspire trial.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.